Abertay Tea for Cardiovascular Health During Menopause

What this trial studies

The regular consumption of seaweed, as observed in Japan, is associated to a reduced cardiovascular risk and prolonged life expectancy. Interventional studies have shown that brown seaweed consumption can reduce blood pressure, improve glycaemic control and lipoprotein profiles, although this varies with population, dose, duration and the type of seaweed. Brown seaweed appears the most promising to improve cardiovascular risk, due to the presence of specific antioxidants (polyphenols called phlorotannins), pigments (fucoxanthin) and fibre (alginate, fucoidan). Women see their cardiovascular risk greatly increased when they reach menopause, and seaweed consumption may provide benefits for this population.

Conditions in scope

• Cardiovascular Risk Factor
• Vascular Function

Interventions

• Nutritional intervention with Fermented Seaweed Enriched English Breakfast Tea (Other) — Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea + 1 g fermented seaweed) into 250mL…
• Nutritional intervention with Control English Breakfast Tea (Other) — Participants will consume 3 cups of tea per day - spread out during the day, for 8 weeks. For each cup, they will be asked to briefly stir one tea bag (3g tea) into 250mL boiling water and let it…

Who can join

Women only · Ages 45 Years to 74 Years · Accepts healthy volunteers.

Inclusion criteria

• Postmenopausal status: no menstrual period over the last 12 months
• Regular tea drinkers (at least once a week), willingness to consume 3 cups of English breakfast tea per day for 8 weeks
• BMI between 18.5 and 39.99 kg/m2

Exclusion criteria

• Reported history of CVD (myocardial infarction, angina, venous thrombosis, stroke, dyslipidemia), diabetes (or fasting glucose ≥ 6.1 mmol/L), kidney, liver or bowel disease.
• Recent history of cancer (\<1y)
• History indicative of a congenital or acquired platelet or haemostatic defect.
• Presence of gastrointestinal disorder or use of drug, which is likely to alter gastrointestinal motility or nutrient absorption.
• Recent use of hypolipidaemic, antiplatelet or antithrombotic medications
• Impairment of thyroid function
• Current smokers or vapers
• Current self-reported weekly alcohol intake exceeding 14 units

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Recruiting
• Study type: Interventional
• Phase: N/A
• Start date: 2025-06-16
• Primary completion: 2025-10
• Last update posted: 2025-07-17
• First posted: 2025-07-17

Sponsor & contact

Lead sponsor: Abertay University (Other)

Collaborators: Oshun Labs Ltd, UK Research and Innovation

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Continuous Non Invasive Arterial Blood Pressure (CNAP) measurements = Continuous Systolic Blood Pressure (Change from baseline at week 8)
  All the non-invasive vascular measurements will be performed in the seated position on the non-dominant arm. The participant will be given a minimum of 5 min rest, time during which a continuous non invasive arterial pressure (CNAP®) monitor will be fitted on their arm and fingers as per the manufacturer's instructions. The participant will be asked to remain as relaxed…

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.